Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPSR Capstar Special Purpose Acquisition	$24.27 +0.1%	$8.28	$6.06 ▼ $12.23	$837.31M	0.07	556,189 shs	636 shs
CRNX Crinetics Pharmaceuticals	$29.96 -0.1%	$31.47	$24.10 ▼ $70.00	$2.81B	0.28	817,528 shs	1.64 million shs
MRUS Merus	$52.99 -0.4%	$48.89	$33.19 ▼ $62.98	$3.67B	1.04	743,249 shs	457,851 shs
VKTX Viking Therapeutics	$26.52 -5.9%	$27.19	$18.92 ▼ $81.73	$2.98B	0.65	4.01 million shs	6.32 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPSR Capstar Special Purpose Acquisition	0.00%	+0.76%	+1.14%	+2.86%	+271.67%
CRNX Crinetics Pharmaceuticals	0.00%	-0.66%	-2.06%	-10.67%	-33.11%
MRUS Merus	0.00%	-0.21%	-4.85%	+25.90%	-10.44%
VKTX Viking Therapeutics	0.00%	+1.96%	-1.70%	+9.81%	-49.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPSR Capstar Special Purpose Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	3.5658 of 5 stars	3.5	0.0	0.0	3.7	2.6	2.5	0.0
MRUS Merus	1.9401 of 5 stars	3.6	1.0	0.0	0.0	2.0	2.5	0.0
VKTX Viking Therapeutics	4.3678 of 5 stars	4.5	1.0	0.0	4.7	1.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPSR Capstar Special Purpose Acquisition	0.00	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	148.85% Upside
MRUS Merus	3.14	Buy	$84.64	59.72% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	228.63% Upside

Current Analyst Ratings Breakdown

Latest CPSR, VKTX, CRNX, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPSR Capstar Special Purpose Acquisition	N/A	N/A	N/A	N/A	($1.18) per share	N/A
CRNX Crinetics Pharmaceuticals	$1.04M	2,697.26	N/A	N/A	$14.29 per share	2.10
MRUS Merus	$54.73M	67.01	N/A	N/A	$9.46 per share	5.60
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPSR Capstar Special Purpose Acquisition	-$15.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/6/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest CPSR, VKTX, CRNX, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPSR Capstar Special Purpose Acquisition	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPSR Capstar Special Purpose Acquisition	N/A	0.13	0.13
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
MRUS Merus	N/A	5.86	5.86
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPSR Capstar Special Purpose Acquisition	64.87%
CRNX Crinetics Pharmaceuticals	98.51%
MRUS Merus	96.14%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
CPSR Capstar Special Purpose Acquisition	N/A
CRNX Crinetics Pharmaceuticals	6.00%
MRUS Merus	4.57%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPSR Capstar Special Purpose Acquisition	2	34.50 million	N/A	Not Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	88.01 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

CPSR, VKTX, CRNX, and MRUS Headlines

Recent News About These Companies

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

...

June 29 at 8:36 AM | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note

June 27 at 6:46 PM | zacks.com

HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)

June 27 at 2:19 AM | americanbankingnews.com

Why This Weight Loss Drug Company's Stock Surged Today

June 26, 2025 | fool.com

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

June 26, 2025 | zacks.com

VKTX Viking Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock Holdings Increased by International Assets Investment Management LLC

June 26, 2025 | marketbeat.com

Oppenheimer & Co. Inc. Acquires 23,481 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 26, 2025 | marketbeat.com

Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity

June 25, 2025 | msn.com

Viking Therapeutics (NASDAQ:VKTX) Receives "Buy" Rating from HC Wainwright

June 25, 2025 | marketbeat.com

Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735

June 25, 2025 | prnewswire.com

My 5 Favorite Dirt Cheap Stocks to Buy Right Now

June 24, 2025 | fool.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.8% - Here's Why

June 23, 2025 | marketbeat.com

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

June 21, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know

June 20, 2025 | msn.com

Institute for Wealth Management LLC. Purchases 9,735 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 19, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

MN Wealth Advisors LLC Has $450,000 Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)

June 18, 2025 | marketbeat.com

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

June 16, 2025 | zacks.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Sold by Handelsbanken Fonder AB

June 16, 2025 | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Shares Down 5.7% - Should You Sell?

June 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

CPSR, VKTX, CRNX, and MRUS Company Descriptions

Capstar Special Purpose Acquisition NYSE:CPSR

Capstar Special Purpose Acquisition Corp. is a blank check company. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses in the consumer, healthcare, and technology, media and telecommunications industries. The company was incorporated in 2020 and is based Austin, Texas.

Crinetics Pharmaceuticals NASDAQ:CRNX

$29.96 -0.03 (-0.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$30.36 +0.40 (+1.35%)

As of 08:56 AM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Merus NASDAQ:MRUS

$52.99 -0.19 (-0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$54.49 +1.50 (+2.84%)

As of 08:00 AM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Viking Therapeutics NASDAQ:VKTX

$26.52 -1.65 (-5.86%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$26.86 +0.34 (+1.28%)

As of 08:57 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time